Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative direction, according to Goldman analyst Salveen Richter. Consequently ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The stock has dropped 56% over the last 12 months. Analysts led by Salveen Richter lowered Moderna's rating to neutral from buy as they say Moderna has limited visibility on the revenue stream for ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

The S&P500 closed in the red on Friday, after the week saw a massive sell-off of AI-related stocks sparked by worries around ...